Boehringer Ingelheim Austria

Boehringer Ingelheim Austria, founded in 1885, is a research-driven pharmaceutical and healthcare company dedicated to developing innovative new treatment approaches that provide outstanding value for patients. Operating within the critical sectors of Pharmaceuticals and Healthcare, the company's core mission revolves around advancing medical science to address unmet needs. Its strategic focus is on pioneering novel therapies through rigorous research and development, aiming to create breakthrough medications.

To achieve its ambitious goals, Boehringer Ingelheim Austria significantly increases its commitment to external innovation, actively collaborating with top partners from academia and industry worldwide. This growing network of academic collaborations underscores the company's focus on emerging science that holds the potential for future medical advancements. Employing between 1,000-5,000 individuals, the company generated approximately $1.6B in revenue. This collaborative spirit extends to its workforce, where one can learn more about the dedicated professionals driving these initiatives by visiting Meet Boehringer Ingelheim Austria's team.

The company's product portfolio encompasses biopharmaceutical and medicinal therapies, emphasizing a holistic approach to both human and animal health. Boehringer Ingelheim Austria is committed to exploring new scientific avenues that could lead to the development of next-generation medications. Their dedication to patient well-being and scientific progress positions them as a key player in the global healthcare landscape, consistently striving to deliver superior therapeutic solutions.